Figure 1 O-GlcNAcylation is critical for MLL5b-AP-1 recruitment to the HPV16/18-LCR and inhibition of O-GlcNAcylation exhibits selective cytotoxicity to HPV16/18 + cells. (A) O-GlcNAcylation inhibitor Azaserine (45 mM, 20 h) downregulated E6/E7 levels, while O-GlcNAcylation activator PUGNAc (150 mM, 20 h) upregulated E6/E7 levels in HeLa and SiHa cells. (B) Azaserine decreased MLL5b O-GlcNAcylation levels resulting in the loss of MLL5b-AP-1 interaction, while PUGNAc increased MLL5b O-GlcNAcylation and MLL5b-AP-1 interaction in co-immunoprecipitation (IP) assays. Competition blots using 0.5 M free GlcNAc were included to control for the specificity of the anti-O-GlcNAc antibody. (C) Azaserine decreased MLL5b recruitment to the LCR, while PUGNAc increased MLL5b-LCR interaction in quantitative chromatin IP (qChIP) assays. (D) Re-ChIP assay of vehicle-, Azaserine-, or PUGNAc-treated cells with O-GlcNAc IP followed by Flag-MLL5b IP. (E and F) Knockdown of OGT decreased Role of MLL5b GlcNAcylation in E6/E7 transcription |
Dear Editor,
Cervical cancer is one of the leading causes of cancer death in women (Munoz et al., 2004) , and current treatment strategies though effective still possess limitations. Thus, identification of more molecular-targeted therapeutics for cervical cancer is urgently needed. We recently identified an isoform of mixed lineage leukemia 5 (MLL5b, 503 amino acids) that is specifically expressed in HPV16/ 18 + cervical cancer cell lines and patient samples (Yew et al., 2011) . MLL5b was found to regulate E6/E7 oncogene transcription activation through its interaction with AP-1 at the 5 ′ segment of the HPV16/ 18-long control region (LCR). With no known DNA-binding motifs on MLL5b, interaction of MLL5b with AP-1 (c-Fos/ c-Jun, AP-1 dimer) was thought to be essential for its recruitment to the HPV16/ 18-LCR (Yew et al., 2011) . As E6 and E7 are the main pathological factors of HPV16/18 + cervical cancer, the development of new therapeutics for this type of cancer has been focused on the inhibition of E6/E7 expression (Butz et al., 2003; Putral et al., 2005) . The identification of the essential role of MLL5b in E6/E7 transcriptional regulation (Yew et al., 2011) poses MLL5b as an attractive molecular target. A further understanding of the molecular mechanisms underlying recruitment and assembly of the MLL5b -AP-1 transcriptional activation complex to the HPV16/18-LCR could provide new insights into MLL5b-targeted therapeutics. Here, we report the essential role of MLL5b O-GlcNAcylation in MLL5b -AP-1 complex assembly at the HPV16/18-LCR and the selective cytotoxic effects of O-GlcNAcylation inhibition on HPV16/18 + cervical cancer cells. Our findings highlight the potential of targeting MLL5b O-GlcNAcylation as a novel therapeutic approach for HPV16/ 18 + cervical cancer.
Several studies have proposed that O-GlcNAcylation is important in mediating histone-modifying activity of SET domaincontaining transcription complexes and their subsequent effects on transcription activation (Deplus et al., 2013; Zhou et al., 2013) . To establish the role of O-GlcNAcylation in MLL5b-mediated E6/E7 transcriptional activation, we determined the effects of O-GlcNAcylation inhibition or activation, by utilizing known O-GlcNAcylation inhibitor Azaserine and activator PUGNAc, respectively, on E6/E7 expression in SiHa (HPV16 + ) and HeLa (HPV18 + ) cells. We found that inhibition of O-GlcNAcylation decreased E6/E7 levels and activation of O-GlcNAcylation increased E6/E7 expression ( Figure 1A) . These were linked to MLL5b O-GlcNAcylation levels and MLL5b assembly into the MLL5b -AP-1 complex at the HPV16/18-LCR. While Azaserine inhibited MLL5b O-GlcNAcylation and its ability to associate with AP-1 and the LCR, enhancement of MLL5b O-GlcNAcylation by PUGNAc was accompanied by increased association with AP-1 and the LCR in coimmunoprecipitation (co-IP) and Chromatin-IP (ChIP) assays ( Figure 1B and C). To further determine whether O-GlcNAcylated MLL5b was indeed recruited to the HPV16/ 18-LCR, a re-ChIP assay was performed where O-GlcNAcylated proteins were first immunoprecipitated with anti-O-GlcNAc antibody and eluted. Elutes were then subjected to a second IP with anti-Flag antibody, and the amount of bound DNA was analyzed by quantitative PCR. The results confirmed that O-GlcNAcylated MLL5b was indeed recruited to the LCR, and the modulation of O-GlcNAcylation affected the amount of O-GlcNAcylated MLL5b associated with the LCR ( Figure 1D ). We also examined effects of direct OGT inhibition with OGT-siRNA (siOGT) on MLL5b O-GlcNAcylation status and its recruitment to the MLL5b-AP-1 complex at the LCR. OGT knockdown inhibited MLL5b O-GlcNAcylation resulting in loss of MLL5b-AP-1 interaction and MLL5b recruitment to the LCR ( Figure 1E and F), cumulating to the downregulation of E6/E7 ( Figure 1G ). Interestingly, OGT was noted to be a part of the complex ( Figure 1E) , suggesting that it was required for E6/E7 transcription activation. To understand the role of MLL5b O-GlcNAcylation in MLL5b-AP-1 complex assembly at the HPV16/18-LCR, we went on to identify the key O-GlcNAcylation site on MLL5b that was essential for the complex assembly. Initial analysis of MLL5b protein sequence using a O-GlcNAcylation site prediction software (http://cbsb.lombardi. georgetown.edu/OGAP.html) identified four potential O-GlcNAcylation sites in MLL5b (Supplementary Figure S1A ). Sitedirected mutagenesis of these sites to alanine residues followed by immunoblotting with anti-O-GlcNAc antibody of the immunoprecipitated Flag-tagged mutants indicated T440 as the key O-GlcNAcylation site in MLL5b ( Figure 1H ). Computational modeling further suggested the location of T440 in the solvent-exposed flexible loop of the MLL5b-SET domain, which was predicted to have a similar fold to the MLL1-SET domain (Supplementary Figure  S1B) . This concurred with a recent report that O-GlcNAcylation preferentially occurred at the solvent flexible loop of 22 proteins with known crystal structures (Liu et al., 2014) . To further delineate the role of O-GlcNAcylation at T440 in MLL5b-AP-1 complex assembly at the HPV16/18-LCR, we studied the ability of MLL5b-T440A and MLL5b phosphomimetic mutant MLL5b-T440E to assemble into the MLL5b-AP-1 complex at the HPV16/18-LCR. The T440E mutant was generated to exclude the role of phosphorylation in the recruitment process, as O-GlcNAcylation had been widely reported to compete directly with phosphorylation at the same Ser/Thr residue. As shown in Figure 1I and J, both mutants lost their ability to assemble into the MLL5b-AP-1 complex at the HPV16/ 18-LCR, highlighting the key role of MLL5b O-GlcNAcylation in the assembly of the MLL5b-AP-1 transcription activation complex. Next, we examined whether MLL5b O-GlcNAcylation at T440 also affected E6/ E7 transcription activation in HeLa cells. Only exogenous wild-type MLL5b was able to maintain E6/E7 expression in MLL5b knockdown cells, while both T440A and T440E mutants could not ( Figure 1K ). As expected, treatment with PUGNAc did not enhance the ability of cells expressing T440A and T440E mutations to maintain E6/E7 levels after MLL5b knockdown (Supplementary Figure S2 ), suggesting that T440 is the key O-GlcNAcylation site essential for successful E6/E7 transcription activation. As T440 is located in the MLL5b-SET domain, we also examined whether O-GlcNAcylation at T440 affected the histone methyltransferase (HMT) activity of MLL5b. The HMT enzymatic activities of MLL5b-T440A and SET mutants harboring catalytically dead SET-domain mutations C411A (Rea et al., 2000) and Y358A (Yew et al., 2011) were tested in vitro. While the T440A mutation in MLL5b had no significant effect on H3K4me3 levels in vitro, C411A and Y358A mutations reduced the ability of MLL5b to tri-methylate core histones (Supplementary Figure S3) . Taken together, these data suggest that O-GlcNAcylation at T440 of MLL5b plays a major role in the recruitment and assembly of the MLL5b -AP-1 transcription activation complex at the HPV16/18-LCR. Figure 1L summarizes the key finding in this study that O-GlcNAcylation at T440 of the MLL5b-SET domain is crucial for the initiation of MLL5b-AP-1 transcriptional complex assembly at the HPV16/18-LCR and subsequent activation of E6/E7 transcription (upper panel) . Inhibiting this posttranslational modification (PTM) by siOGT or O-GlcNAcylation inhibitors resulted in dissolution of the MLL5b-AP-1 complex at the HPV16/18-LCR and subsequent loss of E6/E7 expression (lower panel). Given the specificity of MLL5b expression in HPV16/ 18 + cervical cancer, we further explored the potential of inhibiting MLL5b O-GlcNAcylation as a novel therapeutic approach for HPV16/18 + cervical cancer, by measuring cell viability upon O-GlcNAcylation inhibition in HPV16/18-positive SiHa and HeLa cells, normal diploid fibroblast WI38, primary human keratinocytes (HK), and HPV16/18-negative C33A. OGT knockdown by siOGT showed significant reduction in the viability of SiHa and HeLa cells after 72 h, compared with WI38, HK, and C33A ( Figure 1M) . Similarly, treatment with O-GlcNAcylation inhibitor Azaserine showed significant loss of cell viability in SiHa and HeLa (solid markers) when compared with three HPV-negative cell lines (open markers) ( Figure 1N) . It is worth mentioning that the doses of Azaserine have been titrated to determine the best selective cytotoxicity to HPV16/18 + cells at 72 h for clinical relevance. The enhanced susceptibility of HPV16/18 + cells to O-GlcNAcylation inhibition by both siOGT and Azaserine was correlated to the downregulation of the E6/E7 oncogene levels ( Figure 1G and Supplementary Figure S4 ). This could be attributed to the inhibited MLL5b recruitment to the HPV16/18-LCR region. Our data, coupled with recent reports suggesting that nontransformed cells are less sensitive to O-GlcNAcylation inhibition (Lynch et al., 2012; Ma et al., 2013) , strongly favor the proposed use of such inhibitors as a potential therapeutic agent for HPV16/18 + cervical cancer with higher specificity to HPV16/18 + cancer cells.
In summary, we are the first to show that O-GlcNAcylation of MLL5b at T440 residue is critical for MLL5b recruitment to the HPV16/18-LCR through its interaction with AP-1. Our data suggest that MLL5b O-GlcNAcylation at T440 is an important initiation step in a multistep process required for E6/E7 transcription activation regulated by the HPV16/18-LCR. Finally, we report the selective cytotoxicity of O-GlcNAcylation inhibition to HPV16/18 + cervical cancer cells, highlighting the potential of applying O-GlcNAcylation inhibitors in HPV16/18 + cervical cancer therapy. 
